Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Roche acquired Spark Therapeutics for $4.3B for gene therapy including Luxturna.
Feb 2023: Roche took ~CHF 740M impairment on Spark assets (Luxturna + hemophilia A/B + Pompe), part of ~$3B in 2022 gene-therapy/oncology write-downs, citing…
April 3, 2025: Roche-owned Spark Therapeutics laying off 337 of ~650 employees (more than half its workforce) in three waves (May, July, December 2025);…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Roche acquired Spark Therapeutics for approximately $4.3 billion ($114.50 per share) in an all-cash tender offer, gaining Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a genetic disease, along with a hemophilia gene therapy pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Spark Therapeutics Inc. (this deal) | 2019 | $4.3B | 27 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Gene Therapy deals